| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $93.3M | -1.1% |
| SG&A Expense | $27.9M | -12.1% |
| Operating Income | -$121.2M | +3.8% |
| Net Income | -$116.9M | +0.8% |
| EPS (Basic) | -$1.70 | +2.9% |
| EPS (Diluted) | -$1.70 | +2.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $81.9M | +161.3% |
| Short-term Investments | $10.0M | -90.6% |
| Current Assets | $96.5M | -31.5% |
| Total Assets | $142.9M | -27.9% |
| Current Liabilities | $18.6M | +19.5% |
| Total Liabilities | $46.2M | -2.5% |
| Stockholders' Equity | $96.7M | -35.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$99.7M | +0.6% |
| Capital Expenditures | $229K | -78.6% |
| Investing Cash Flow | $96.9M | +36.4% |
| Financing Cash Flow | $53.4M | +1717.3% |
| Free Cash Flow | -$99.9M | +1.5% |